Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cian HealthcareBOM:542678 49 Net Margin % is -105.86% as of Mar. 2026. GuruFocus rates BOM:542678 with a GF Score™ of 49/100 and a GF Value™ of ₹82.33 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 959 Drug Manufacturers companies, Cian Healthcare ranks worse than 89.78% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Cian Healthcare's Net Income for the
six
months ended in Mar. 2026 was ₹-179.7 Mil. Cian Healthcare's Revenue for the
six
months ended in Mar. 2026 was ₹169.8 Mil. Therefore, Cian Healthcare's net margin for the quarter that ended in Mar. 2026 was -105.86%.
The historical rank and industry rank for Cian Healthcare's Net Margin % or its related term are showing as below:
BOM:542678'
s Net Margin % Range Over the Past 10 Years
Min: -84.35 Med: 0.56 Max: 6.74
Current: -78.31
BOM:542678's Net Margin % is ranked worse than 89.78% of 959
companies
in the Drug Manufacturers industry
Industry Median: 5.32
vs BOM:542678: -78.31
Cian Healthcare (BOM:542678) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Cian Healthcare Net Margin % Related Terms
Cian Healthcare Net Margin % Historical Data
* Premium members only.
The historical data trend for Cian Healthcare's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:542678 vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cian Healthcare's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cian Healthcare Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cian Healthcare's Net Margin % distribution charts can be found below:
* The bar in red indicates where Cian Healthcare's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cian Healthcare (BOM:542678) has a Net Margin % of -105.86% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Cian Healthcare and its competitors. According to the industry distribution chart, Cian Healthcare ranks #861 out of 959 companies in the Drug Manufacturers industry, placing it in the top 89.8%.
Is Cian Healthcare's Net Margin % too high?
Cian Healthcare's current Net Margin % is -105.86%. Based on the distribution chart, Cian Healthcare ranks #861 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cian Healthcare has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cian Healthcare's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cian Healthcare ranks #861 out of 959 companies for Net Margin %. This places Cian Healthcare in the lower half of its industry. The industry median Net Margin % is 5.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.32, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Cian Healthcare and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cian Healthcare's current Net Margin % is -105.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cian Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Cian Healthcare (BOM:542678) is currently considered Possible Value Trap. The stock's GF Value™ is ₹82.33, compared to a current price of ₹9.55 — trading 88.4% below its estimated fair value. The current Net Margin % is -105.86%. Cian Healthcare's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Cian Healthcare (BOM:542678), the current Net Margin % is -105.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cian Healthcare (BOM:542678) Overvalued in 2026?
Based on GuruFocus' analysis, Cian Healthcare stock appears to be undervalued.
The current stock price of ₹9.55 is trading 88.4% below its estimated GF Value™ of ₹82.33.
GuruFocus considers Cian Healthcare to be Possible Value Trap.
Key valuation signals for BOM:542678:
Net Margin %: -105.86%
GF Value™: ₹82.33 vs. price of ₹9.55 (88.4% below fair value)
No single metric tells the full story. See the BOM:542678 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cian Healthcare Ltd is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company manufactures multiple product lines, including tablets, capsules, soft gels, liquid orals, ointments/creams and sachets, and cosmetics. Its portfolio comprises gynecology, haematinic, cardio-diabetic, orthopedic, pediatric, dermacosmetic, antibiotic, CNS, vitamins, and nutrient products. The company operates in five sectors: Export, Government Supplies, Merchant Export, Own Brand Franchise Business, and Third Party/Contract Manufacturing.
49GF Score
Get the complete analysis for BOM:542678
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542678 has been successfully added to your 
